Ivonescimab

HARMONi Phase 3: Ivonescimab Confirms PFS Benefit; OS Primary Endpoint Not Met, Nominal in Follow-Up Analysis

Summit Therapeutics’ Ivonescimab demonstrates statistically significant PFS improvement in the global HARMONi trial. OS did not meet the pre-specified threshold in the primary analysis, but longer follow-up in Western patients shows a nominal supportive trend for regulatory review.

Bispecific Antibodies

Beyond Ivonescimab: China’s Next $Billion PD-1/VEGF Bispecific Licensing Opportunities

With blockbuster deals by 3SBio, BioNTech, and Akeso, emerging Chinese PD-1/VEGF bispecifics like RC148, HB0025, JS207, and CS2009 are primed for billion-dollar licensing opportunities.

Ivonescimab

Ivonescimab Secures Pivotal OS Win in NSCLC: Redefining the PD-1/VEGF Bispecific Landscape

Akeso’s Ivonescimab achieves pivotal OS milestone in EGFR-mutant NSCLC, outperforming Keytruda and cementing its role in the PD-1/VEGF bispecific market.